(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.46% ¥ 2 644.00
Live Chart Being Loaded With Signals
CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model...
Stats | |
---|---|
Объем за сегодня | 283 600 |
Средний объем | 40 111.00 |
Рыночная капитализация | 44.64B |
EPS | ¥0 ( 2024-04-26 ) |
Last Dividend | ¥5.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.48 |
ATR14 | ¥3.11 (0.00%) |
Объем Корреляция
CMIC HOLDINGS Co., Ltd. Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
CMIC HOLDINGS Co., Ltd. Корреляция - Валюта/Сырье
CMIC HOLDINGS Co., Ltd. Финансовые показатели
Annual | 2023 |
Выручка: | ¥104.70B |
Валовая прибыль: | ¥24.70B (23.59 %) |
EPS: | ¥416.23 |
FY | 2023 |
Выручка: | ¥104.70B |
Валовая прибыль: | ¥24.70B (23.59 %) |
EPS: | ¥416.23 |
FY | 2022 |
Выручка: | ¥108.46B |
Валовая прибыль: | ¥26.26B (24.21 %) |
EPS: | ¥469.41 |
FY | 2021 |
Выручка: | ¥85.79B |
Валовая прибыль: | ¥17.73B (20.66 %) |
EPS: | ¥111.87 |
Financial Reports:
No articles found.
CMIC HOLDINGS Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥10.00 (N/A) |
¥0 (N/A) |
¥5.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2004-09-27 |
Last Dividend | ¥5.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 39 | -- |
Total Paid Out | ¥394.60 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.76 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.88 | |
Div. Directional Score | 7.89 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9069.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7956.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7187.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6432.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
5411.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4433.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
3612.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
2818.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
1446.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9740.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0572 | 1.500 | 8.86 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0785 | 1.200 | 7.38 | 8.86 | [0 - 0.3] |
returnOnEquityTTM | 0.147 | 1.500 | 9.48 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.01 | 0.800 | 4.97 | 3.97 | [1 - 3] |
quickRatioTTM | 1.503 | 0.800 | 5.87 | 4.69 | [0.8 - 2.5] |
cashRatioTTM | 0.617 | 1.500 | 7.69 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0385 | -1.500 | 9.36 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 57.84 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0737 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.223 | 1.000 | 9.61 | 9.61 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0745 | 1.000 | -0.509 | -0.509 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.93 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.372 | 0.800 | 4.19 | 3.35 | [0.5 - 2] |
Total Score | 11.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.38 | 1.000 | 9.25 | 0 | [1 - 100] |
returnOnEquityTTM | 0.147 | 2.50 | 9.67 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.702 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 453.56 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.740 | 1.500 | -8.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0823 | 1.000 | -0.443 | 0 | [0.1 - 0.5] |
Total Score | 3.88 |
CMIC HOLDINGS Co., Ltd.
CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, clinical caretaker, medical writing, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. CMIC HOLDINGS Co., Ltd. has a partnership with Science 37, Inc. to decentralize clinical trials and enhance the development of treatments. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа